Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 Saint Herblain (France) and Schlieren (Zurich), November 13, 2024...
Valneva et LimmaTech annoncent la vaccination du premier participant à l’essai d’infection contrôlée de Phase 2b du candidat vaccin tétravalent contre la shigellose S4V2 Saint Herblain (France) et...
Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage...
Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe Saint-Herblain (France), le 12 novembre 2024 – Valneva SE (Nasdaq: VALN; Euronext...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Saint-Herblain (France), November 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a...
Saint-Herblain (France), November 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in...
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of...
Valneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2024 et fait un point sur ses activités Principaux éléments financiers pour les neuf premiers mois de l’exercice...
Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher...
VALNEVA - Déclaration d’actions et de droits de vote : 31 octobre 2024 VALNEVA Déclaration d’actions et de droits de vote 31 octobre 2024___________________________________________________________...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.314 | -13.0182421227 | 2.412 | 2.43 | 2.074 | 596586 | 2.16758867 | DE |
4 | -0.592 | -22.0074349442 | 2.69 | 2.804 | 2.074 | 457368 | 2.41929939 | DE |
12 | -1.16 | -35.6046654389 | 3.258 | 3.426 | 2.074 | 539179 | 2.6517235 | DE |
26 | -1.852 | -46.8860759494 | 3.95 | 4.298 | 2.074 | 525605 | 3.12742345 | DE |
52 | -3.762 | -64.1979522184 | 5.86 | 5.898 | 2.074 | 517090 | 3.49324845 | DE |
156 | -19.562 | -90.3139427516 | 21.66 | 29.7 | 2.074 | 606770 | 10.34890474 | DE |
260 | -0.397 | -15.9118236473 | 2.495 | 29.7 | 1.784 | 670247 | 10.98908017 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관